Humulin N (Nph) Kwikpen

Humulin N (Nph) Kwikpen is a pre‑filled subcutaneous pen injector that contains insulin human (recombinant DNA) in an intermediate‑acting NPH formulation. It is supplied in a KwikPen device and is marketed in the European Union as a prescription‑only product for the management of diabetes. The pen delivers a consistent dose of insulin and may be used as part of a comprehensive diabetes care plan under medical supervision.

Humulin N (Nph) Kwikpen is indicated for use in adults and children with diabetes who require basal insulin coverage.

- Type 1 diabetes mellitus requiring basal insulin. - Type 2 diabetes mellitus when oral agents are insufficient. - As part of a basal‑bolus regimen combined with rapid‑acting insulin. - When a longer‑acting insulin is preferred to reduce daily injection frequency. - In combination with oral antidiabetic agents for comprehensive glucose control.

Like other insulin products, Humulin N may cause adverse reactions at the injection site or systemic effects related to glucose control.

Common: - Hypoglycemia, especially if meals are missed or delayed. - Injection‑site pain, redness, swelling, or bruising. - Local lipodystrophy such as lipoatrophy or lipohypertrophy.

Serious: - Severe hypoglycemia with loss of consciousness or seizures. - Anaphylactic or severe allergic reaction (e.g., urticaria, angioedema). - Fluid retention, edema, or worsening of heart failure.

Before starting Humulin N, patients and healthcare providers should consider several safety factors to minimize risks.

- Check blood glucose before each injection and adjust dose as needed. - Reduce the dose during illness, pregnancy, or when using systemic corticosteroids. - Rotate injection sites to prevent lipodystrophy. - Monitor for signs of hypoglycemia, particularly in elderly or renally impaired patients. - Avoid use if there is a known hypersensitivity to human insulin or any excipient. - Store the KwikPen according to the label and discard after the indicated period after opening. - Review all concomitant medications that may affect insulin action or mask hypoglycemia.

Humulin N can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use of other insulin products without appropriate dose adjustment. - Beta‑blockers that may mask typical hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas) that increase hypoglycemia risk. - Systemic corticosteroids that raise blood glucose levels. - Alcohol consumption that can cause delayed hypoglycemia.